The Polycomb repressive system is an essential chromatin-based regulator of gene expression. Despite being extensively studied, how its target genes are selected and whether its histone modifying activities are required for transcriptional repression remains controversial. Here, we directly test the requirement for PRC1 catalytic activity in Polycomb system function. We demonstrate that a mutation widely used to disrupt PRC1 catalysis is hypomorphic, complicating the interpretation of previous studies. To overcome this, we develop a new inducible mutation system in embryonic stem cells that completely ablates PRC1 catalytic activity, revealing that catalysis by PRC1 drives Polycomb chromatin domain formation and higher-order chromatin interactions. In the absence of catalysis, we uncover the primary DNA-based targeting determinants that direct Polycomb target site selection. Finally, we discover that Polycomb-mediated gene repression requires PRC1 catalytic activity. Together these discoveries provide compelling new evidence supporting a PRC1-initiated pathway for Polycomb system function in gene regulation.
Introduction
Eukaryotic DNA is wrapped around histone octamers to form nucleosomes and chromatin which organise DNA within the confines of the nucleus. In addition to this essential packaging role, histones are also post-translationally modified and this has been proposed to regulate important chromatinbased processes (Atlasi and Stunnenberg, 2017; Kouzarides, 2007; Musselman et al., 2012b) . For example, removal of enzymes that modify histones around gene promoters can lead to alterations in gene expression (Bannister and Kouzarides, 2011) . However, these enzymes often contain multiple highly conserved domains, some of which are not required for catalysis, and typically form large multiprotein complexes (DesJarlais and Tummino, 2016; Schuettengruber et al., 2017) . This has made it challenging to understand the extent to which the catalytic activity of histone modifying enzymes and the modifications that they place contribute to nuclear processes such as transcription. The Polycomb repressive system is an essential regulator of developmental gene expression (reviewed in Blackledge et al., 2015; Di Croce and Helin, 2013; Schuettengruber et al., 2017) . Polycomb group (PcG) proteins typically belong to one of two multiprotein complexes that have chromatin modifying activity: Polycomb Repressive Complex 1 (PRC1) is an E3 ubiquitin ligase that mono-ubiquitylates histone H2A at lysine 119 (to form H2AK119ub1) (de Napoles et al., 2004; Wang et al., 2004a) and Polycomb Repressive Complex 2 (PRC2) is a methyltransferase that mono-, di-and tri-methylates histone H3 at lysine 27 (to form H3K27me1, me2 and me3) (Cao et al., 2002; Czermin et al., 2002; Kuzmichev et al., 2002; Muller et al., 2002) . PRC1 and PRC2 can recognize target gene promoters and form Polycomb chromatin domains that are characterised by high-level enrichment of these complexes and the histone modifications that they deposit (Mikkelsen et al., 2007) . Perturbations in Polycomb repressive complexes can lead to alterations in the levels of H2AK119ub1 and H3K27me3, and misexpression of Polycomb target genes (Boyer et al., 2006; Endoh et al., 2008; Endoh et al., 2017; Fursova et al., 2019; Leeb et al., 2010; Pasini et al., 2007; Rose et al., 2016) . In turn, these molecular pathologies can cause developmental abnormalities and other human disease states (Pasini and Di Croce, 2016; Poynter and Kadoch, 2016; Richly et al., 2011) .
It has been widely proposed that Polycomb chromatin domains are formed via a PRC2-initiated mechanism, in which PRC2 is actively recruited to Polycomb target genes via DNA binding accessory subunits, transcription factors or non-coding RNAs (Brockdorff, 2013; Dietrich et al., 2012; Herranz et al., 2008; Li et al., 2010; Li et al., 2017; Perino et al., 2018) and deposits H3K27me3 that is recognised by chromodomain-containing CBX proteins within so-called canonical PRC1 (cPRC1) complexes (Cao et al., 2002; Min et al., 2003; Wang et al., 2004b) . cPRC1 complexes can support local chromatin compaction and long-range interactions between Polycomb chromatin domains, which has been proposed to underpin Polycomb-mediated gene repression (Eskeland et al., 2010; Francis et al., 2004; Grau et al., 2011) . However, we and others have recently provided evidence for an alternative PRC1initiated mechanism for Polycomb chromatin domain formation. This relies on a class of variant PRC1 (vPRC1) complexes which have DNA binding activities and do not require H3K27me3 for target site recognition Blackledge et al., 2015; Cooper et al., 2014; Endoh et al., 2017; Tavares et al., 2012) . In this alternative model, we propose that, in the absence of transcription, deposition of H2AK119ub1 at gene promoters by vPRC1 complexes drives PRC2 occupancy, Polycomb chromatin domain formation and protection against aberrant gene activation events.
A fundamental distinction between the PRC2 and PRC1-initiated models for Polycomb chromatin domain formation lies in their requirement for PRC1 catalysis and H2AK119ub1. In the PRC2-initiated model, PRC1 catalytic activity is proposed to be dispensable for recruitment of cPRC1 complexes, longrange chromatin interactions, and gene repression (Eskeland et al., 2010; Illingworth et al., 2015; Kundu et al., 2017) . In contrast, the PRC1-initiated model relies on H2AK119ub1 as the driving force behind Polycomb chromatin domain formation and ultimately gene repression Cooper et al., 2014) . Previous attempts to test the requirement for PRC1 catalysis in Polycombmediated gene repression in mammals have yielded conflicting outcomes (Endoh et al., 2012; Eskeland et al., 2010; Illingworth et al., 2015; Kundu et al., 2017) , and as such its contribution to Polycomb system function remains controversial. Therefore, despite the vertebrate Polycomb system being one of the most extensively studied chromatin-based gene regulation paradigms, there is still an active debate as to whether PRC1-or PRC2-initiated pathways drive Polycomb chromatin domain formation and transcriptional repression (Blackledge et al., 2015; Schuettengruber et al., 2017; Simon and Kingston, 2009; Steffen and Ringrose, 2014) . As a consequence, the mechanisms that underpin Polycomb-mediated gene repression remain elusive.
Here, we systematically dissect the role of PRC1 catalysis in Polycomb-mediated gene regulation. Using reconstituted PRC1 complexes and in vitro ubiquitylation assays, coupled with in vivo experiments in mouse embryonic stem cells (ESCs), we reveal that mutations previously employed to disrupt catalysis by PRC1 are hypomorphic and do not eliminate H2AK119ub1 in cells. We develop a new catalytic mutant of PRC1 that completely ablates E3 ubiquitin ligase activity in vitro and use this as a basis to develop a sophisticated conditional point mutant system that rapidly converts PRC1 into a catalytically inactive form in vivo. This leaves PRC1 complexes intact, but completely abrogates H2AK119ub1. Using this system, we discover that catalysis by PRC1 is a central requirement for PRC2 binding and activity at Polycomb target sites, as well as occupancy of cPRC1 complexes and long-range chromatin interactions that they mediate. Furthermore, in the absence of PRC1 catalytic activity, we reveal the existence of a DNA-based sampling mechanism inherent to vPRC1 complexes that underpins Polycomb target site selection and Polycomb chromatin domain formation. Finally, and most importantly, we discover that loss of PRC1 catalysis largely phenocopies the gene expression defects caused by complete removal of PRC1. Together, these discoveries reveal a fundamental requirement for the catalytic activity of PRC1 in Polycomb chromatin domain formation and gene repression in ESCs, supporting a PRC1-initiated mechanism for Polycomb system function in gene regulation.
Results

Establishing a catalytically inactive PRC1 complex
To test the importance of PRC1 E3 ubiquitin ligase activity for Polycomb system function, we required a highly validated mutant version of PRC1 completely lacking catalytic activity. PRC1 complexes form around either RING1A or RING1B, which dimerise with one of six PCGF proteins (PCGF1-6) (Gao et al., 2012; Kloet et al., 2016) . cPRC1 complexes utilize PCGF2 or 4, whereas vPRC1-specific complexes incorporate PCGF1/3/5/6. To achieve catalysis, RING1A/B interact with an E2 ubiquitin-conjugating enzyme to promote transfer of ubiquitin to H2AK119, with the PCGF and other PRC1 complex components regulating this activity (Buchwald et al., 2006; Rose et al., 2016) . Structural information detailing how a minimal cPRC1 complex, composed of PCGF4 and RING1B, interfaces with its cognate E2 enzyme UbcH5c was originally used to define a catalytic mutation in which isoleucine 53 of RING1B was changed to alanine (I53A) ( Figure 1A ) (Bentley et al., 2011; Buchwald et al., 2006) . This mutation disrupts the interaction between RING1B and the E2, resulting in loss of E3 ubiquitin ligase activity in vitro. Based on these in vitro observations, RING1B I53A has been used in a number of in vivo studies to examine the role of catalysis by PRC1, with most concluding that PRC1 catalytic activity contributes modestly to Polycomb system function (Cohen et al., 2018; Endoh et al., 2012; Eskeland et al., 2010; Illingworth et al., 2015; Pengelly et al., 2015) . However, we and others have recently demonstrated that vPRC1 complexes are far more catalytically active than cPRC1 complexes, both in vitro and in vivo Gao et al., 2012; Morey et al., 2013; Rose et al., 2016) . Therefore, we wanted to test whether RING1B I53A is indeed catalytically inactive in the context of a more enzymatically competent PRC1 complex. To this end we reconstituted the highly active PCGF1/RING1B/RYBP vPRC1 complex containing either wild-type RING1B or RING1B I53A ( Figure 1B) . We then carried out in vitro ubiquitylation assays on reconstituted nucleosome substrates. As expected, wild-type PRC1 ubiquitylated histone H2A efficiently ( Figure 1C and D). However, surprisingly, complexes containing RING1B I53A still ubiquitylated H2A, albeit to reduced levels ( Figure 1C and D). This indicates that RING1B I53A -PRC1, at least in vitro, is hypomorphic and retains some catalytic activity.
To develop a version of PRC1 which completely lacks catalytic activity, we decided to combine the I53A mutation with a second mutation, aspartate 56 to lysine (D56K), which was also shown to interfere with the RING1B-E2 interaction (Bentley et al., 2011) (Figure 1A) . Importantly, in our in vitro E3 ubiquitin ligase assay, RING1B I53A/D56K -PRC1 produced no detectable H2A ubiquitylation (Figure 1C and D) . Together these in vitro experiments demonstrate that RING1B I53A is hypomorphic, whereas RING1B I53A/D56K is catalytically inactive. Importantly, these observations suggest that the interpretation of experiments in which RING1B I53A has been used to inactivate PRC1 require reconsideration.
RING1B catalytic mutations are not sufficient to eliminate H2AK119ub1
Having characterised the activity of RING1B I53A and RING1B I53A/D56K -PRC1 complexes in vitro, we next wanted to examine how these mutations affected H2AK119ub1 in cells. Therefore, we used CRISPR/Cas9-mediated genome engineering to introduce I53A or I53A/D56K mutations into endogenous Ring1b in mouse ESCs (Figure 2A ). Western blot analysis revealed that RING1B levels were similar in RING1B WT , RING1B I53A and RING1B I53A/D56K cells ( Figure 2B ), and co-immunoprecipitation showed that PRC1 complexes with wild-type or mutated RING1B formed normally ( Figure 2C ). We then measured total H2AK119ub1 levels by western blot. Remarkably, this revealed that about 30% of H2AK119ub1 remained in the RING1B I53A cells, with RING1B I53A/D56K cells showing an additional modest, yet significant, reduction in H2AK119ub1 to about 20% of wild type levels ( Figure 2B ). We next used calibrated chromatin immunoprecipitation sequencing (cChIP-seq) to profile H2AK119ub1 in RING1B WT , RING1B I53A , and RING1B I53A/D56K cells (Bonhoure et al., 2014; Hu et al., 2015; Orlando et al., 2014) . In agreement with the western blot analysis, this revealed that levels of H2AK119ub1 were majorly reduced in RING1B I53A cells and further reduced in RING1B I53A/D56K cells, but it was not completely lost ( Figure 2D -G). This was evident both for RING1B-bound sites with high levels of H2AK119ub1 (Figure 2E and F) and the low-level blanket of H2AK119ub1 that we recently demonstrated covers the genome ( Figure 2G ) . Importantly, in both RING1B I53A and RING1B I53A/D56K ESCs, RING1B target sites retained considerable levels of H2AK119ub1 ( Figure 2E and F). Given that RING1B I53A/D56K -PRC1 showed no apparent enzymatic activity in vitro, we were surprised to observe that such high levels of H2AK119ub1 were retained in RING1B I53A/D56K cells. We hypothesised that this remaining H2AK119ub1 may come from the activity of the RING1B paralogue, RING1A, which is also expressed in ESCs, albeit at lower levels (Endoh et al., 2008) . To test this possibility, we set out to introduce analogous catalytically inactivating mutations into RING1A (I50A/D53K). Generation of RING1A I50A/D53K ESCs was highly efficient, but when we tried to combine RING1A I50A/D53K with RING1B I53A/D56K , no RING1A I50A/D53K ;RING1B I53A/D56K ESCs were obtained.
In summary, our western blot and cChIP-seq analyses demonstrate that a considerable amount of H2AK119ub1 is retained in RING1B I53A ESCs, indicating that this mutation cannot be used to draw conclusions on the requirement for PRC1 catalysis and H2AK119ub1 in Polycomb system function. Furthermore, the retention of H2AK119ub1 in the RING1B I53A/D56K line indicates that RING1Bcontaining PRC1 complexes do not account for all H2AK119ub1 in ESCs and that RING1A must contribute significantly to the catalytic activity of PRC1. Our inability to isolate cells with both RING1A I50A/D53K and RING1B I53A/D56K suggests that PRC1 catalysis may be essential for ESC viability and Polycomb system function.
A conditional point mutant system to inactivate PRC1 catalysis
Since we were unable to generate constitutive RING1A I50A/D53K ;RING1B I53A/D56K mutant cells, we needed to develop a new system to study whether PRC1 catalysis is required for Polycomb system function in vivo. We reasoned that this could be achieved by generating a cell line in which removal of catalysis could be conditionally induced. To do this, we engineered both endogenous Ring1b alleles to contain an I53A/D56K mutant version of the exon encoding the E2 interaction domain in the antisense orientation downstream of the corresponding wild-type exon ( Figure 3A and Figure S1C ). This wildtype/mutant exon pair was flanked by inverted double LoxP/Lox2272 sites and the cells were engineered to express tamoxifen-inducible CRE recombinase. In the absence of tamoxifen (OHT), wild-type RING1B would be expressed, but addition of tamoxifen would lead to an inversion event causing the cells to express catalytically inactive RING1B I53A/D56K ( Figure 3A-B) . Importantly, to eliminate the contribution of RING1A, we also constitutively inactivated both alleles of the endogenous Ring1a gene by introducing RING1A I50A/D53K mutations ( Figure 3B ).
To validate the functionality of the PRC1 conditional point mutant (PRC1 CPM ) system, we confirmed that exon inversion occurred efficiently and Ring1b mRNA encoding the I53A/D56K mutation was exclusively expressed after 72 hours of tamoxifen treatment (Figure S1A-C). Importantly, RING1B protein levels were largely unchanged following addition of tamoxifen, but in contrast to constitutive RING1B I53A and RING1B I53A/D56K mutant cells, we now observed a complete loss of H2AK119ub1 as measured by bulk histone western blot in tamoxifen-treated PRC1 CPM cells ( Figure 3C ). To ensure that H2AK119ub1 was completely abrogated genome-wide, we carried out cChIP-seq for H2AK119ub1. This demonstrated that H2AK119ub1 was no longer found at sites enriched for RING1B or throughout the genome ( Figure 3D -G, Figure S1D ).
In order to compare the molecular defects that arise from catalytic inactivation of PRC1 with those that manifest following complete removal of PRC1, we also developed an isogenic ESC line, in which both copies of Ring1a were constitutively deleted, the first coding exon of both Ring1b alleles was flanked by parallel LoxP sites, and the cells were engineered to express tamoxifen-inducible CRE recombinase ( Figure 3B and Figure S1E ). In this PRC1 conditional knockout (PRC1 CKO ) cell line, RING1B and H2AK119ub1 were completely lost following 72 hours of tamoxifen treatment ( Figure 3C ). Importantly, the loss of H2AK119ub1 in the tamoxifen-treated PRC1 CKO was identical to that observed in the PRC1 CPM cells, when analysed by western blot and cChIP-seq ( Figure 3C and Figure 3D -G, Figure   S1D and F). The combination of isogenic conditional catalytic point mutant (PRC1 CPM ) and conditional knockout (PRC1 CKO ) ESC lines ( Figure 3B ) now provided us with the opportunity to directly test the PRC1-initiated model for Polycomb chromatin domain formation and ultimately define whether catalysis by PRC1 is required for Polycomb system function and gene repression.
PRC2 binding and deposition of H3K27me3 at Polycomb target sites rely on PRC1 catalytic activity
We have previously demonstrated that removal of PRC1 results in a dramatic reduction of PRC2 and H3K27me3 levels at Polycomb target genes in line with a PRC1-initiated mechanism for Polycomb chromatin domain formation Fursova et al., 2019; Rose et al., 2016) . However, much milder effects on PRC2 and H3K27me3 were observed in RING1B I53A ESCs (Illingworth et al., 2015) , suggesting that the catalytic activity of PRC1 may not solely dictate Polycomb chromatin domain formation. With the knowledge that RING1B I53A cells retain significant amounts of H2AK119ub1, we set out to use our new PRC1 CPM ESCs, in which complete loss of H2AK119ub1 could be induced, to directly test whether PRC1 catalytic activity is required for normal PRC2 targeting and H3K27me3 deposition. To do this, we performed cChIP-seq for the core PRC2 component SUZ12, and H3K27me3, in the PRC1 CPM and PRC1 CKO ESCs before and after tamoxifen treatment. In untreated cells, SUZ12 binding occurred at sites also occupied by RING1B ( Figure 4A , Figure S2A -B), but strikingly in the tamoxifen-treated PRC1 CPM cells we observed a dramatic reduction in the levels of both SUZ12 and H3K27me3 at these sites ( Figure 4A , B, D, and E, Figure S2C -D). Importantly, these changes recapitulated the effects on PRC2 observed when PRC1 was removed in the PRC1 CKO cells ( Figure 4F -G, Figure S2C -D).
Biochemical studies have identified two subtypes of PRC2 complexes with distinct targeting modules (reviewed in Laugesen et al., 2019; Yu et al., 2019) . The PRC2.1 complex contains PCL proteins, which have been shown to bind to non-methylated CpG-rich DNA and methylated histone tails (Ballare et al., 2012; Brien et al., 2012; Cai et al., 2013; Li et al., 2017; Musselman et al., 2012a; Perino et al., 2018) , while the PRC2.2 complex contains the JARID2 subunit, which has been recently implicated in direct recognition of H2AK119ub1 (Cooper et al., 2016; Kalb et al., 2014) . Based on the major reductions in SUZ12 binding and H3K27me3 levels in the tamoxifen-treated PRC1 CPM cells, we wanted to test whether occupancy of PRC2.1 and PRC2.2 was differentially affected by loss of PRC1 catalytic activity. Consistent with the proposed role of JARID2 as a reader of H2AK119ub1, cChIP-seq in PRC1 CPM cells revealed an almost complete loss of JARID2 binding at PcG-occupied sites following tamoxifen treatment ( Figure 4A , C and H, Figure S2E ). Interestingly, we also observed a reduction in JARID2 protein levels following loss of PRC1 catalytic activity ( Figure S2F ), suggesting that chromatin binding is required for its stability. Next, we examined the contribution of PRC1 catalytic activity to PRC2.1 occupancy by performing cChIP-seq for PCL2, a subunit specific to this complex. This revealed that in the tamoxifen-treated PRC1 CPM cells PCL2 occupancy at PcG-occupied sites was reduced, albeit to a lesser extent than JARID2 ( Figure 4A , C and I, Figure S2E and G), while PCL2 protein levels were largely unaffected ( Figure S2F ). A possible explanation for this somewhat surprising result could be that, while PCL proteins confer DNA binding activity to the PRC2.1 complex, occupancy of PRC2.1 also relies on EED-dependent recognition of H3K27me3 (Margueron et al., 2009) , the levels of which are strongly diminished in the absence of PRC1 catalytic activity ( Figure 4A , B and E). Together, these observations demonstrate that both PRC2.1 and PRC2.2 rely heavily on PRC1 catalytic activity for binding to Polycomb target sites.
In the nucleus, PcG proteins have been shown to form cytological foci, called Polycomb bodies, that contain Polycomb-repressed genes and are highly enriched for Polycomb-associated factors (Cheutin and Cavalli, 2012; Ren et al., 2008; Saurin et al., 1998) . To examine whether the major reductions in PRC2 enrichment observed at target sites in fixed cells by cChIP-seq were also evident in live cells, we added a HaloTag to the endogenous SUZ12 protein in the PRC1 CPM cells and used live-cell imaging to examine SUZ12 localisation in the nucleus before and after tamoxifen treatment. In untreated PRC1 CPM cells, we observed approximately one hundred SUZ12 nuclear foci per cell with a wide range of sizes and intensities ( Figure 4J and Figure S2H ). Following tamoxifen treatment and loss of PRC1 catalytic activity, the number, size, and intensity of SUZ12 foci was dramatically reduced, indicating that normal PRC2 localisation was also disrupted in live cells ( Figure 4J and K, Figure S2H and I). Together, these results demonstrate that high-level PRC2 occupancy and H3K27me3 deposition at Polycomb target sites relies heavily on the catalytic activity of PRC1, supporting a PRC1-initiated mechanism for Polycomb chromatin domain formation.
PRC1 catalytic activity drives canonical PRC1 occupancy and higher-order chromatin interactions
At Polycomb target sites, PRC2-deposited H3K27me3 is recognised by cPRC1 complexes which are proposed to mediate long-range interactions between Polycomb chromatin domains (Kundu et al., 2017; Schoenfelder et al., 2015) . Previous work has reported that these long-range chromatin interactions are diminished in RING1B knockout cells but intact in RING1B I53A cells (Eskeland et al., 2010; Kundu et al., 2017) , leading to the conclusion that Polycomb chromatin domain interactions do not rely on catalysis by PRC1. Given the hypomorphic nature of RING1B I53A cells and our new observations that H3K27me3 levels are dramatically reduced in the PRC1 CPM cells following tamoxifen treatment, we wanted to determine whether cPRC1 binding and higher-order chromatin interactions were affected when PRC1 catalysis was completely removed. We therefore carried out cChIP-seq for PCGF2, a core component of cPRC1 complexes in ESCs (Morey et al., 2015) . In untreated PRC1 CPM cells, PCGF2 was enriched at RING1B-bound regions with high levels of PRC2 and H3K27me3 ( Figure 5A , Figure S3A and B). Importantly, PCGF2 binding at target sites was largely lost in the tamoxifen-treated PRC1 CPM cells ( Figure 5A -C, Figure S3C ). Furthermore, protein levels of cPRC1-specific subunits were reduced following tamoxifen treatment, suggesting that a failure to bind chromatin destabilizes the cPRC1 complex ( Figure 5D ).
Next, we examined whether loss of cPRC1 binding following removal of PRC1 catalytic activity had an effect on long-range interactions between Polycomb chromatin domains. To achieve this, we used a chromosome conformation capture-based approach, called CaptureC , to examine interaction profiles for 24 classical Polycomb target sites that are highly enriched with PCGF2 and RING1B ( Figure S3D ). Strikingly, this revealed that long-range interactions formed between these regions and other classical Polycomb target sites were largely abolished in the tamoxifen-treated PRC1 CPM cells and this effect was highly comparable to the complete removal of PRC1 ( Figure 5E and F, Figure S3E ). Together, these observations further support a PRC1-initiated hierarchical recruitment model in which PRC1 catalytic activity is a primary requirement for a sequence of downstream events which culminate in the formation of Polycomb chromatin domains that can engage in long-range interactions ( Figure 5G ).
DNA-based sampling activities of vPRC1 complexes drive target site selection by PRC1
The mechanisms that are responsible for the selection of target sites at which repressive Polycomb chromatin domains form remain poorly understood. cPRC1 complexes account for a significant proportion of RING1B occupancy at established Polycomb chromatin domains Morey et al., 2015) , but this is a downstream consequence of PRC1 catalysis ( Figure 5 ). Therefore, we reasoned that in the absence of PRC1 catalytic activity and cPRC1 binding, the primary mechanisms responsible for target site selection may be revealed. To examine this possibility, we carried out cChIPseq for RING1B in the PRC1 CPM cells before and after tamoxifen treatment and compared RING1B occupancy to the binding of other Polycomb factors and chromatin features. In untreated PRC1 CPM cells, binding of RING1B correlated strongly with the levels of PCGF2 and PRC2 (SUZ12 and H3K27me3), consistent with a prominent role for cPRC1 in shaping RING1B occupancy in wild-type cells ( Figure 6A , D and E and Figure S4A , E and F). Following tamoxifen treatment, RING1B binding was majorly reduced at sites that normally have high levels of PRC1 and PRC2 in untreated cells, and now correlated only modestly with cPRC1 or PRC2 occupancy ( Figure 6A , D and E, Figure S4A -B and S4E-F). Surprisingly, however, RING1B levels were unchanged or even increased in tamoxifen-treated PRC1 CPM ESCs at a large number of sites that normally have low to moderate enrichment of PRC1 and PRC2 ( Figure 6A and D and Figure S4A and B). Importantly, similar effects were observed using live-cell imaging of Polycomb foci in untreated and tamoxifen-treated PRC1 CPM cells in which we added a HaloTag to the endogenous RING1B protein. Following loss of PRC1 catalysis, the total number, average size and intensity of foci were only modestly reduced ( Figure 6B and C, Figure S4C ). However, we observed a dramatic reduction in the number of bright foci, while the number of less intense foci was largely unaffected, in agreement with our cChIP-seq analysis ( Figure 6B and C, Figure S4C and D). Together this reveals that while high-level enrichment of RING1B at target sites forming Polycomb chromatin domains requires PRC1 catalytic activity, there exists low-level RING1B binding across all target sites that is independent of PRC1 catalysis.
To understand the mechanisms defining RING1B targeting in the absence of PRC1 catalytic activity, we turned our attention to the PCGF1-and PCGF6-containing vPRC1 complexes, both of which incorporate DNA binding modules. The PCGF1-PRC1 complex contains KDM2B, a ZF-CXXC domain protein that binds non-methylated CpGs He et al., 2013; Wu et al., 2013) , while PCGF6-PRC1 incorporates MAX/MGA DNA binding factors (Gao et al., 2012; Hauri et al., 2016; Kloet et al., 2016; Ogawa et al., 2002) . In untreated PRC1 CPM cells, cChIP-seq for PCGF1 and PCGF6 revealed a broad and generally uniform binding of both factors across all RING1B-occupied sites, which correlated poorly with RING1B levels ( Figure 6A , D and E, Figure S4A and G). Importantly, in the tamoxifen-treated PRC1 CPM cells, we observed a strong correlation of RING1B occupancy with binding of PCGF1 and PCGF6, as well as with non-methylated CpG-rich DNA and MAX levels ( Figure 6A and E and S4G and H). Furthermore, occupancy of PCGF1 and PCGF6 was only modestly affected by loss of PRC1 catalytic activity, indicating that binding of these vPRC1 complexes is largely independent and upstream of PRC1 catalysis and Polycomb chromatin domain formation ( Figure 6A and D, Figure S4A and B). These observations strongly suggest that DNA binding activities inherent to PCGF1-and PCGF6containing vPRC1 complexes constitute the primary targeting mechanisms that underpin target site selection by PRC1.
We and others have previously proposed that transcription may directly or indirectly counteract the formation of Polycomb chromatin domains (Jermann et al., 2014; Klose et al., 2013; Riising et al., 2014) . In support of this idea, in untreated PRC1 CPM cells, the highest levels of RING1B and PCGF2 were associated with promoters of lowly transcribed genes that were enriched for H3K27me3 and H2AK119ub1, but not H3K4me3, a histone modification enriched at transcribed genes ( Figure 6A and F, Figure S4I and J). In contrast, more actively transcribed RING1B targets exhibited low levels of H2AK119ub1, PRC2, H3K27me3 and cPRC1, despite being occupied by similar levels of the PCGF1 and PCGF6 vPRC1 complexes ( Figure 6A and F, Figure S4I and J). Importantly, in tamoxifen-treated PRC1 CPM cells, strong enrichment of RING1B at lowly transcribed genes was lost, uncovering an underlying and largely uniform distribution of RING1B across target sites which mirrored the occupancy PCGF1 and PCGF6 ( Figure 6A , D and F, Figure S4I and J). Together these observations are consistent with a model in which the PCGF1-and PCGF6 vPRC1 complexes broadly engage with, or sample, Polycomb target sites via their DNA binding domains, which, in the absence of counteracting features associated with active transcription, can lead to high-level H2AK119ub1 deposition and subsequent Polycomb chromatin domain formation.
The catalytic activity of PRC1 is required for Polycomb-mediated gene repression
PRC1 is essential for Polycomb chromatin domain formation and this relies on catalysis (Figures 4-6), but whether PRC1 catalytic activity is also required for transcriptional repression still remains unresolved. To directly address this fundamental question, we carried out calibrated RNA-seq (cRNAseq) in the isogenic PRC1 CPM and PRC1 CKO ESCs before and after tamoxifen treatment. Loss of PRC1 in PRC1 CKO cells resulted in a dramatic derepression of Polycomb target genes ( Figure 7A and S5A), which is consistent with the central role of PRC1 in Polycomb-mediated gene repression in ESCs (Endoh et al., 2008; Fursova et al., 2019) . Strikingly, removal of PRC1 catalysis resulted in reactivation of a similar number of Polycomb target genes ( Figure 7A and Figure S5A ), indicating that the catalytic activity of PRC1 is essential for Polycomb-mediated gene repression.
A more detailed comparison of the gene expression alterations in the tamoxifen-treated PRC1 CKO and PRC1 CPM ESCs revealed that the magnitude of gene expression changes strongly correlated between these cell lines, both when looking at all genes and specifically at PRC1-repressed genes ( Figure 7B and S5B and C). This demonstrates that loss of PRC1 catalytic activity largely phenocopies the gene expression defects that manifest when PRC1 is completely removed. However, we found a small number of PRC1-repressed genes (241 out of 2482) which appeared to be derepressed to a lesser extent in the PRC1 CPM compared to the PRC1 CKO ESCs following tamoxifen treatment ( Figure 7D , F and G). These tended to have large Polycomb chromatin domains that were highly enriched with cPRC1 and H3K27me3 in untreated cells and retained low level of cPRC1 binding in the tamoxifen-treated PRC1 CPM cells ( Figure 7E and Figure S5D and E). Nevertheless, repression of this small subset of genes still relied heavily on PRC1 catalysis, as removal of cPRC1 alone caused only a modest increase in their expression ( Figure 7F ). Importantly, the remaining PRC1-repressed genes were reactivated to the same level in PRC1 CPM and PRC1 CKO ESCs following tamoxifen treatment ( Figure 7C and G), indicating that PRC1 catalysis is a central determinant of gene repression. Therefore, through systematically dissecting the requirement for PRC1 catalytic activity in Polycomb system function, we provide direct evidence that this activity is essential for both Polycomb chromatin domain formation and gene repression.
Discussion
The Polycomb system represents a paradigm for chromatin-based gene regulation. However, the mechanisms by which Polycomb target sites are identified and repressive Polycomb chromatin domains are formed have remained elusive. Moreover, the extent to which this relies on PRC1 catalysis is still controversial. Here, using in vitro enzymatic assays and genome engineering in ESCs, we discover that a mutation (RING1B I53A ) previously used to study the role of PRC1 catalysis in Polycomb system function, is not catalytically inactive (Figures 1 and 2) . We develop an elegant conditional strategy to completely ablate PRC1 catalytic activity while leaving PRC1 complexes intact ( Figure 3 ). Using this new tool, we discover that catalysis by PRC1 is essential for PRC2 occupancy and H3K27me3 deposition at target sites, together with downstream recruitment of cPRC1 complexes which support long-range interactions between Polycomb chromatin domains . We show that DNA-binding vPRC1 complexes broadly occupy target sites independently of PRC1 catalysis and that this likely represents a primary mechanism of Polycomb target site selection prior to Polycomb chromatin domain formation ( Figure 6 ). Finally, and most importantly, we demonstrate that the catalytic activity of PRC1 is essential for Polycomb-mediated gene repression ( Figure 7 ). Together, these discoveries demonstrate a central requirement for PRC1 catalysis in gene repression and provide compelling new evidence for a PRC1-initiated pathway that drives Polycomb chromatin domain formation and gene repression.
Understanding whether catalysis by chromatin modifying enzymes is central to their function is an ongoing challenge in the field of chromatin biology. Definitive interpretations can only be arrived at when in vitro biochemical characterisations demonstrate that inactivating mutations cause complete loss of catalysis without protein complex disruption. Furthermore, this must be combined with quantitative measurements of the modified substrate in vivo, to ensure that the product of catalysis is completely lost in the cellular context. Here we satisfy these two central requirements for studying PRC1 catalytic activity, whose contribution to Polycomb system function has remained controversial. Importantly, we discover that catalysis by PRC1 is essential for normal Polycomb chromatin domain formation and gene repression. While we have limited our investigation to ESCs, where the Polycomb system has been extensively characterised, a recent study has also examined the contribution of PRC1 catalytic activity to gene regulation using a neuronal cell fate restriction model (Tsuboi et al., 2018) . In agreement with our observations in ESCs, it was reported that RING1B I53A mutation is hypomorphic, while RING1B I53A/D56K is catalytically inactive. Furthermore, from expression analysis of a small number of neurogenic genes, this study concluded that PRC1 catalytic activity is required for gene repression during the early stages of neurogenic commitment. Interestingly, however, at later stages of neuronal lineage specification, gene repression did not appear to rely solely on PRC1 catalysis. This suggests that catalysis-independent mechanisms may contribute to the maintenance of gene repression in more slowly-or non-dividing cells that are characteristic of later developmental stages, as has been previously proposed (Cohen et al., 2018) . Moving forward, it will be important to use the catalytic mutations we have extensively characterised to examine at the genome scale how widely the enzymatic activity of PRC1 contributes to Polycomb system function during mammalian development. Furthermore, these mutations should also be used in other model organisms, such as Drosophila, where the contribution of PRC1 catalysis to gene regulation and development has been proposed to be more limited (Pengelly et al., 2015) .
Defining the mechanisms of Polycomb target site selection and repressive Polycomb chromatin domain formation is central to understanding the logic by which the Polycomb system functions. In mammalian cells, high-level Polycomb occupancy occurs at CpG island (CGI) elements (Mikkelsen et al., 2007) , while ectopic GC-rich DNA is sufficient to establish a new Polycomb chromatin domain de novo (Jermann et al., 2014; Lynch et al., 2012; Mendenhall et al., 2010) . A mechanistic link between CGIs and Polycomb recruitment came with the discovery that KDM2B, a component of the PCGF1containing vPRC1 complex, has DNA binding activity which is specific for non-methylated CpG dinucleotides, suggesting that recognition of CGI DNA may underpin Polycomb target site selection He et al., 2013; Wu et al., 2013) . Similarly, the PCGF6-containing vPRC1 complex has DNA binding activities that contribute to Polycomb occupancy in specialised contexts (Endoh et al., 2017; Zdzieblo et al., 2014) or more generally Scelfo et al., 2019; Yang et al., 2016) . However, while PCGF1 and PCGF6 broadly occupy target sites, somewhat paradoxically only a subset of these achieve high levels of PRC1, H2AK119ub1, PRC2 and H3K27me3 ( Figure 6 ). Here, using our PRC1 CPM ESCs, we provide new evidence for a model in which the PCGF1-and PCGF6-containing vPRC1 complexes utilise their DNA binding activities to sample all potential Polycomb target genes, but high-level deposition of H2AK119ub1 and subsequent Polycomb chromatin domain formation occurs only at target genes with low transcriptional activity. This model is supported by previous work showing that the Polycomb system responds to, as opposed to instructs, the transcriptional state of a gene (Berrozpe et al., 2017; Hosogane et al., 2013; Riising et al., 2014) . We propose that at lowly transcribed genes a PRC1-initiated pathway that relies on catalysis is required to protect against lowlevel stochastic gene activation events that would otherwise be deleterious to maintenance of cell type-specific gene expression programmes.
Our observations reveal that catalysis by PRC1 is essential for Polycomb-mediated gene repression, but how is this achieved mechanistically? We recently demonstrated that removal of cPRC1 complexes in ESCs has little effect on Polycomb-mediated gene repression , while earlier work showed that PRC2 removal and loss of H3K27me3 resulted in few gene expression defects (Riising et al., 2014) , suggesting that these activities may play a secondary role and instead contribute to the fidelity of gene repression. Based on these findings, it seems unlikely that the role of PRC1 catalysis and H2AK119ub1 is simply to recruit PRC2, H3K27me3 and cPRC1 complexes to elicit gene repression. One possibility is that H2AK119ub1 could directly disrupt RNA Polymerase II activity (Stock et al., 2007; Zhou et al., 2008) , as recently suggested by in vitro transcription assays, in which incorporation of H2AK119ub1 into recombinant chromatin templates blocked transcription (Aihara et al., 2016; Nakagawa et al., 2008) . Alternatively, PRC1 catalytic activity and H2AK119ub1 could have an indirect effect on transcription, for example by creating a binding site for reader proteins which would then elicit repression (Ali et al., 2018; Cooper et al., 2016; Qin et al., 2015; Richly et al., 2010; Zhang et al., 2017) . In addition, incorporation of a bulky ubiquitin moiety may interfere with deposition of other histone modifications that facilitate gene expression (Nakagawa et al., 2008; Yuan et al., 2013) . Finally, the possibility that PRC1 drives gene repression via ubiquitylation of histone H2A variants (Surface et al., 2016) or other non-histone substrates cannot be ruled out (Ben-Saadon et al., 2006) . Clearly, future work focussed on defining the mechanisms by which the catalytic activity of PRC1 counteracts RNA Polymerase II activity and gene expression will be important. Nevertheless, our new discoveries place PRC1 catalysis at the forefront of Polycomb-mediated gene repression, paving the way for a mechanistic understanding of Polycomb function. (A) A schematic of the crystal structure illustrating the RING1B-PCGF4 dimer bound to E2 ubiquitin conjugating enzyme (UBCH5C) (PDB ID: 3RPG) (Bentley et al., 2011) . The key amino acids that mediate RING1B-E2 interaction are indicated. (B) Coomassie-stained gels of affinity-purified RING1B-PCGF1-RYBP complexes incorporating wild-type or mutated forms of RING1B. (C) In vitro E3 ubiquitin ligase assays carried out using reconstituted nucleosomes. Conversion of unmodified H2A to more slowly migrating ubiquitylated forms were measured by western blot with an H2A-specific antibody and an H3-specific antibody was used as a control. See also Figure S5 . (A) Bar plots showing the overlap between RING1B-and SUZ12-bound genomic regions. This illustrates that PRC1 and PRC2 share a large number of target sites, with > 95% of SUZ12 peaks overlapping with RING1B peaks, while RING1B binding appears to be more broad. (B) Heatmap analysis of cChIP-seq in PRC1 CKO ESCs for RING1B (untreated and OHT-treated), SUZ12 and H3K27me3 (untreated) at RING1B-bound sites divided into two groups based on the overlap with SUZ12 peaks (RING1B/SUZ12-bound or PcG-occupied (n = 7074) and only 569) ). For each group, the genomic regions were sorted based on RING1B occupancy in untreated cells. (A) Box plots of cChIP-seq signal for RING1B, PCGF1 and PCGF6 at RING1B-bound sites divided into quartiles based on H3K27me3 levels in untreated cells (from lowest Q1 to highest Q4) in PRC1 CPM ESCs before (UNT, blue) and after OHT treatment (OHT, red) . This shows that PCGF1 and PCGF6 occupancy is largely uniform across all RING1B-bounds sites with different H3K27me3 levels. (B) Box plots comparing changes in cChIP-seq signal for RING1B, PCGF1 and PCGF6 following OHT treatment in PRC1 CPM cells at RING1B-bound sites divided into quartiles based on H3K27me3 levels in untreated cells. Together with (A), this shows that following removal of PRC1 catalytic activity, RING1B occupancy is reduced at sites with high levels of H3K27me3 (Q3 and Q4) but is retained/increased at sites with low levels of H3K27me3 (Q1 and Q2). In addition, it demonstrates that PCGF1 and PCGF6 occupancy is only modestly affected following loss of PRC1 catalytic activity, with binding of PCGF1 slightly increased at sites with low level of H3K27me3 and binding of PCGF6 moderately reduced at sites with high enrichment of H3K27me3. (C) Box plots comparing volumes and mean intensities of RING1B-Halo-JF549 nuclear foci in PRC1 CPM ESCs before (ncells = 69) and after OHT treatment (ncells = 83). P-values denote statistical significance calculated by a Wilcoxon signed-rank test. (D) Box plots comparing numbers of RING1B-Halo-JF549 nuclear foci detected in PRC1 CPM ESCs before (ncells = 69) and after OHT treatment (ncells = 83), with foci divided into quartiles based on foci volume (left) or mean intensities (right) in untreated cells (from lowest Q1 to highest Q4). This shows that loss of PRC1 catalysis had the strongest effect on RING1B nuclear foci with the largest volume and mean intensity, while the foci with low to moderate intensities/volumes remained largely unchanged or even increased. This is in agreement with changes in RING1B occupancy by cChIP-seq at target sites with different levels of RING1B binding in untreated cells. (A) A bar plot illustrating the distribution of gene expression changes (p-adj < 0.05 and > 1. 5-fold) in cRNA-seq between different gene classes (Non-NMI, Non-PcG, PcG) for PRC1 CKO and PRC1 CPM ESCs following OHT treatment. Non-NMI genes (n = 5326) lack a non-methylated CpG island (NMI) at their promoter. Non-Polycomb target genes (n = 9024) have an NMI promoter that is not co-occupied by both Polycomb repressive complexes. Polycomb target genes (n = 6283) have an NMI promoter that is bound by both PRC1 and PRC2. (B) Top panel: A Venn diagram showing the overlap between the genes derepressed (p-adj < 0.05 and > 1.5-fold) in PRC1 CKO (red) and PRC1 CPM (blue) ESCs following OHT treatment.
Bottom panel: Box plots comparing the gene expression levels from cRNA-seq in PRC1 CPM and PRC1 CKO ESCs before (UNT) and after OHT treatment (OHT) for three groups of derepressed genes defined in the Venn diagram above: PRC1 CKO -specific, shared between PRC1 CKO and PRC1 CPM ESCs, and PRC1 CPM -specific. This demonstrates that for the genes categorised as specifically derepressed in either PRC1 CKO or PRC1 CPM OHT-treated ESCs, the magnitude of gene expression changes is more modest than for the shared targets, making them more sensitive to the choice of a significance threshold. Importantly, expression levels of these genes following OHT treatment are highly similar between the two cell lines. (C) A scatter plot comparing the log2 fold changes in gene expression in cRNA-seq following OHT treatment in PRC1 CPM and PRC1 CKO ESCs for PRC1-repressed genes. R 2 represents coefficient of determination for linear regression and cor denotes Pearson correlation coefficient. (D) Box plots of PCGF2 cChIP-seq signal at the RING1B-bound sites associated with the promoters of PRC1-repressed genes which are either partially (n = 241) or fully derepressed (n = 2241) following loss of PRC1 catalysis as compared to a complete loss of PRC1 in PRC1 CPM cells before (UNT) and after OHT treatment (OHT). (E) As in (E) for H3K27me3 cChIP-seq. (F) Box plots comparing sizes of RING1B-bound sites overlapping with the promoters of PRC1repressed genes which are either partially (n = 241) or fully derepressed (n = 2241) following OHT treatment in PRC1 CPM as compared to PRC1 CKO ESCs.
Methods
Recombinant protein expression and purification
Mouse RING1B, tagged with StrepII and 6xHis tags, was coexpressed with PCGF1 and RYBP from a pST44 polycistronic plasmid in E. coli BL21 (DE3) pLysS. Cultures were supplemented during expression with 250 µM ZnCl2. Cells were lysed by sonication in lysis buffer containing 20 mM Tris (pH 8.0), 500 mM NaCl, 0.1% NP-40 and cOmplete Protease Inhibitor Cocktail (Roche) and trimeric complexes were affinity purified via 6xHis-tagged RING1B on Ni 2+ -charged IMAC Sepharose 6 Fast Flow resin (GE Healthcare). 10 mM imidazole was added to lysates during binding. Wash buffer contained 50 mM NaH2PO4 (pH 8.0), 300 mM NaCl and 20 mM imidazole and protein was eluted in wash buffer containing increasing imidazole (100-250 mM). Purified PRC1 complexes were dialysed into BC100 (50 mM HEPES (pH 7.9), 100 mM KCl, 10% Glycerol, 1 mM DTT).
Reconstitution of Nucleosomes
Nucleosomes were reconstituted as described previously (Dyer et al., 2004) . Recombinant Xenopus histones were expressed in E. coli BL21(DE3) pLysS and purified from inclusion bodies via Sephacryl S-200 gel filtration (GE Healthcare). Stoichiometric amounts of each core histone were incubated together under high salt conditions (2 M NaCl) and the resulting histone octamer purified using a Superdex 200 gel filtration column (GE Healthcare). Purified 147bp DNA carrying the 601 nucleosomepositioning sequence was a kind gift from the Brockdorff lab. Purified DNA, in slight excess to octamers, was mixed together in 2 M NaCl and diluted stepwise with 10 mM Tris (pH 7.5) to reach a final concentration of 100 mM NaCl. The reconstituted nucleosomes were analysed on a 0.8% Trisborate agarose gel and concentrated using a 30,000 MWCO spin concentrator (GE Healthcare).
E3 ubiquitin ligase assays
H2A ubiquitylation assays were carried out as previously (Rose et al., 2016) . Briefly, UBE1 (Boston Biochem), UbcH5c (Enzo), methylated ubiquitin (Boston Biochem) and ATP (Life technologies) were pre-incubated for 20 min at 37°C prior to addition of reconstituted PRC1 and nucleosomes. Reactions were allowed to proceed for 1 hr at 37°C then quenched with 30 mM EDTA and subject to SDS-PAGE for western blot analysis. Western blots were probed with antibodies which recognise Histone H2A in both ubiquitylated and unmodified form (Millipore 07-146) and Histone H3 (CST, 96C10), followed by incubation with LiCOR IRDye secondary antibodies (800CW goat anti-rabbit and 680RD goat antimouse). Western blots were imaged using the LiCOR Odyssey Fc imaging system and band intensities were quantified using ImageStudio. H2A band intensities were normalised to H3 and the fraction of ubiquitylated H2A relative to total H2A was quantified. Data were visualised and dose-response curves fitted using GraphPad Prism 7.
Genome engineering by CRISPR/Homology-Directed Repair (HDR)
The pSptCas9(BB)-2A-Puro(PX459)-V2.0 vector was obtained from Addgene (#62988) and sgRNAs were designed using the CRISPOR online tool (http://crispor.tefor.net/crispor.py). Targeting constructs with appropriate homology arms were generated by Gibson assembly using the Gibson Assembly Master Mix kit (New England Biolabs), or in the case of single LoxP sites with 150 bp homology arms, purchased from GeneArt Gene Synthesis (Invitrogen). In all instances, targeting constructs were designed such that Cas9 recognition sites were disrupted by the presence of the LoxP site. ESCs (one well of a 6-well plate) were transfected with 0.5 g of each Cas9 guide, and 2 g of targeting construct (where appropriate) using Lipofectamine 3000 (ThermoFisher) according to manufacturer's guidelines. The day after transfection, cells were passaged at a range of densities and subjected to puromycin selection (1 g/ml) for 48 hours to eliminate any non-transfected cells. Approximately one week later, individual clones were isolated, expanded, and PCR-screened for the desired genomic modification.
Cell line generation
Constitutive Ring1b I53A and Ring1b I53A/D56K ESCs were generated from E14 ESCs using a Cas9 guide specific for the mutation site in the endogenous Ring1b gene, and targeting constructs with approximately 1 kb homology arms. The targeting constructs were designed so that as well as introducing the desired mutation into Ring1b, an MspI restriction site was also created to enable screening of clones via a PCR and digest approach. Putative homozygote clones were carried forward for RT-PCR and sequencing to verify that the Ring1b transcript carried the desired mutation, as well as western blot analysis. An analogous strategy was used to insert the I50A/D53K mutation into Ring1a (see below).
To generate the PRC1 CPM line, a targeting construct was generated comprising exon 3 of Ring1b in forward orientation (flanked by 100 bp of Ring1b intron 2/intron 3) followed by a mutant copy of exon 3 (encoding I53A and D56K mutations) in reverse orientation (flanked by splice donor and acceptor sites from mouse IgE gene). Both the wild-type and mutant versions of exon 3 were codon optimized at wobble positions to minimize sequence similarity, thereby avoiding hairpin formation and allowing the two to be easily distinguished. This exon 3 pair was flanked by doubly inverted LoxP/Lox2272 sites and approximately 1 kb homology arms (see Supplementary Table 1 for sequence). To help ensure that the RING1B CPM cassette was inserted correctly, the RING1B CPM targeting construct was transfected into E14 ESCs in combination with three different Cas9 guides specific for the Ring1b locus (see Supplementary table 1) . Correctly targeted homozygous clones were identified by PCR screening, followed by RT-PCR and sequencing to check for splicing defects. CreERT2 was then inserted into the Rosa26 locus using a Rosa26-specific Cas9 guide, and using a similar approach, the I50A/D53K mutation was constitutively knocked into both copies of endogenous Ring1a. The final PRC1 CPM cell line was validated by PCR, RT-PCR and western blot, with and without tamoxifen treatment.
The isogenic PRC1 CKO line used in this study was described previously . Briefly, exons 1-3 of Ring1a were firstly deleted using Cas9 guides flanking the 1.5 kb deletion region, and Cre-ERT2 was inserted into the Rosa26 locus using a Rosa26-specific guide (see Supplementary Table 1) . Ring1a -/-;CreERT2 ESCs were then subjected to two sequential rounds of genome editing to insert parallel LoxP sites flanking exon 2 (the first coding exon) of Ring1b.
The control TIR1-only and AID-RING1B lines were generated from E14 ESCs as described previously (Rhodes et al., 2019) . Briefly, Cas9 engineering was used to insert the coding sequence for Oryza sativa TIR1 into the Rosa26 locus, thereby generating the TIR1-only control line. To generate the AID-RING1B line, the TIR1-only line was subjected to further rounds of Cas9-mediated engineering to introduce the auxin inducible degron (AID) tag at the N-terminus of both copies of Ring1b, and constitutively delete Ring1a using Cas9 guides flanking exons 1-3. Western blot analysis was used to confirm loss of RING1B protein in AID-RING1B line in response to auxin treatment, and that RING1B levels remained unchanged in auxin-treated TIR1-only control cells.
Preparation of nuclear and histone extracts and immunoblotting
For nuclear extraction, ESCs were washed with PBS and then resuspended in 10 volumes of Buffer A (10 mM Hepes pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, 0.5 mM PMSF and protease inhibitor cocktail (Roche)). After 10 min incubation on ice, cells were recovered by centrifugation at 1500 g for 5 min and resuspended in 3 volumes of Buffer A supplemented with 0.1% NP-40. The released nuclei were pelleted by centrifugation at 1500 g for 5 min, followed by resuspension in 1 volume of Buffer C (5 mM Hepes (pH 7.9), 26 % glycerol, 1.5 mM MgCl 2, 0.2 mM EDTA, protease inhibitor cocktail (Roche) and 0.5 mM DTT) supplemented with 400 mM NaCl. The extraction was allowed to proceed on ice for 1 hour with occasional agitation, then the nuclei were pelleted by centrifugation at 16,000 g for 20 min at 4°C. The supernatant was taken as the nuclear extract.
For histone extraction, ESCs were washed with RSB supplemented with 20 mM NEM, incubated on ice for 10 min in RSB with 0.5% NP-40 and 20 mM NEM, pelleted by centrifugation at 800 g for 5 min and incubated in 2.5 mM MgCl2, 0.4 M HCl and 20 mM NEM on ice for 30 min. After that, cells were pelleted by centrifugation at 16,000 g at 4°C for 20 min, the supernatant recovered and precipitated on ice with 25% TCA for 30 min, followed by centrifugation at 16,000 g for 15 min at 4°C to recover histones. Following two acetone washes, the histones were resuspended in 150 l 1xSDS loading buffer and boiled at 95°C for 5 min. Finally, any insoluble precipitate was pelleted by centrifugation at 16,000 g for 15 min at 4°C and the soluble fraction retained as the histone extract. Histone concentrations across samples were compared by Coomassie Blue staining following SDS-PAGE. Semiquantitative western blot analysis of histone extracts was performed using LI-COR IRDye® secondary antibodies and imaging was done using the LI-COR Odyssey Fc system. To measure the changes in bulk H2AK119ub1 levels, the relative signal of H2AK119ub1 to H3 or H4 histones was quantified.
Co-immunoprecipitation
For co-immunoprecipitation reactions, 400 g of nuclear extract from wild-type or RING1B I53A/D56K ESCs was added to BC150 buffer (150 mM KCl, 10% glycerol, 50 mM HEPES (pH 7.9), 0.5 mM EDTA, 0.5 mM DTT) with 1x protease inhibitor cocktail (Roche) to a total volume of 550 l. A 50 l Input sample was retained, and 5 g of mouse monoclonal anti-RING1B antibody (Atsuta et al., 2001 ) was added to the remaining 500 l of sample. Immunoprecipitation reactions were then incubated overnight at 4 o C. Immunoprecipitated material was collected with Protein A agarose beads and washed four times in 1 ml of BC150 buffer. Following the final wash step, beads were directly resuspended in 100 l of 1x SDS loading buffer (2% SDS, 0.1 M Tris pH 6.8, 0.1 M DTT, 10% glycerol, 0.1% bromophenol blue) and placed at 95 o C for 5 mins. 1x SDS loading buffer was similarly added to Input samples which were also incubated at 95 o C for 5 mins, prior to SDS-PAGE and western blot analysis.
Polycomb body imaging
To image Polycomb bodies in live cells, HaloTag-SUZ12;PRC1 CPM or RING1B-HaloTag;PRC1 CPM cells were plated on gelatinised 35 mm petri dish, 14 mm Microwell 1.5 coverglass dishes (MatTek, #P35G-1.5-14-C) at least 5 hours before imaging. Prior to imaging, cells were labelled with 500 nm JF549 (Grimm et al., 2017) for 15 min at 37°C, followed by 3 washes, changing medium to Fluorobrite DMEM (Thermo Fisher Scientific) supplemented as described for general ESC culture above. Cells were incubated for a further 30 min in supplemented Fluorobrite DMEM with 10 µg/mL Hoechst 33258 (Thermo Fisher Scientific) at 37°C and washed once more before imaging. Cells were imaged on an IX81 Olympus microscope connected to a Spinning Disk Confocal system (UltraView VoX PerkinElmer) using an EMCCD camera (ImagEM, Hamamatsu Photonics) in a 37°C heated, humidified, CO2-controlled chamber. Z-stacks were acquired using a 100x PlanApo NA 1.40 oil-immersion objective heated to 37°C, using Volocity software (PerkinElmer). HaloTag-JF549 was imaged with a 561 nm laser at 1.25 sec exposure at 15% laser power, while Hoechst was imaged with a 405 nm laser at 250 ms exposure at 20% laser power. Z-stacks were acquired at 150 nm intervals.
Capture-C library preparation
CaptureC libraries were prepared as described previously . Briefly, 10 6 mouse ESCs were trypsinized, collected in 50 ml falcon tubes in 9.3 ml media and crosslinked with 1.25 ml 16% formaldehyde for 10 minutes at room temperature. Cells were quenched with 1.5 M glycine, washed with PBS and lysed for 20 minutes at 4°C lysis buffer (10mM Tris pH 8, 10 mM NaCl, 0.2% NP-40, supplemented with complete proteinase inhibitors) prior to snap freezing in 1 ml lysis buffer at -80°C. Lysates were then thawed on ice, pelleted and resuspended in 650 µl 1x DpnII buffer (NEB 
Capture-C hybridization and sequencing
5' biotinylated probes were designed using the online tool by the Hughes lab (CapSequm) to be 70-120bp long and two probes for each promoter of interest. The probes were pooled at 2.9 nM each. Samples were captured twice and hybridizations were carried out for 72h and for 24h for the first and the second captures, respectively. To even out capture differences between tubes, libraries were pooled prior to hybridization at 1.5 µg each. Hybridization was carried out using Nimblegen SeqCap (Roche, Nimblegen SeqCap EZ HE-oligo kit A, Nimblegen SeqCap EZ HE-oligo kit B, Nimblegen SeqCap EZ Accessory kit v2, Nimblegen SeqCap EZ Hybridisation and wash kit) following manufacturer's instructions for 72 hours followed by a 24 hours hybridization (double Capture). The captured library molarity was quantified by qPCR using SensiMix SYBR (Bioline, UK) and KAPA Illumina DNA standards (Roche) and sequenced on Illumina NextSeq 500 platform as 80 bp paired-end reads for three biological replicates.
Massive parallel sequencing, data processing and normalisation
For calibrated ChIP-seq, paired-end reads were aligned to the concatenated mouse and spike-in genome sequences (mm10+dm6 for native cChIP-seq, and mm10+hg19 for cross-linked cChIP-seq) using Bowtie 2 (Langmead and Salzberg, 2012) with the "--no-mixed" and "--no-discordant" options.
Only uniquely mapped reads after removal of PCR duplicates with Sambamba (Tarasov et al., 2015) were used for downstream analysis.
For cRNA-seq, first, paired-end reads were aligned using Bowtie 2 (with "--very-fast", "--no-mixed" and "--no-discordant" options) against the concatenated mm10 and dm6 rDNA genomic sequence (GenBank: BK000964.3 and M21017.1) and reads mapping to rDNA were discarded. All unmapped reads were then aligned against the concatenated mm10 and dm6 genome sequences using STAR (Dobin et al., 2013) . Finally, reads that failed to map using STAR were aligned against the mm10+dm6 concatenated genome using Bowtie 2 (with "--sensitive-local", "--no-mixed" and "--no-discordant" options) to improve mapping of introns. Uniquely aligned reads from the last two steps were combined for further analysis. PCR duplicates were removed using Sambamba (Tarasov et al., 2015) .
For the corresponding gDNA-seq experiments, paired-end read alignment and processing was carried out as described above for cChIP-seq.
For Capture-C, paired-end reads were aligned and filtered for HiC artefacts using HiCUP (Wingett et al., 2015) and Bowtie2 (Langmead and Salzberg, 2012) with fragment filter set to 100-800bp. A list of all Next-Generation sequencing experiments carried out in this study and the number of uniquely aligned reads in each experiment can be found in Table S2 .
For visualisation of cChIP-seq and cRNA-seq data and annotation of genomic regions with read counts, uniquely aligned mouse reads were normalised using dm6 or hg19 spike-in as described previously . Briefly, mm10 reads were randomly subsampled based on the total number of spike-in (dm6 or hg19) reads in each sample. To account for any minor variations in spike-in cell mixing between replicates, we used the ratio of spike-in/mouse total read counts in the corresponding Input/gDNA-seq samples to correct the subsampling factors. After normalisation, read coverages for individual biological replicates were compared across RING1B peaks for cChIP-seq or gene bodies for cRNA-seq using multiBamSummary and plotCorrelation from deepTools (Ramirez et al., 2014) . For each experimental condition, biological replicates correlated well (Pearson correlation coefficient > 0.9, see Table S3 ) and were merged for downstream analysis. Genome coverage tracks were generated using the pileup function from MACS2 (Zhang et al., 2008) for cChIP-seq and genomeCoverageBed from BEDTools (Quinlan, 2014) for cRNA-seq and visualised using the UCSC genome browser (Kent et al., 2002) . BigwigCompare from deeptools (v3.1.1) (Ramirez et al., 2014) was used to make differential genome coverage tracks.
Peak calling
To identify genomic regions bound by RING1B, SUZ12 and PCGF2, we carried out peak calling using MACS2 ("BAMPE" and "--broad" options specified), with corresponding Input samples used as a control. For RING1B and SUZ12, peaks were called using merged biological replicates from untreated PRC1 CPM and PRC1 CKO cells for RING1B and SUZ12 cChIP-seq respectively, and only peaks identified in both cell lines were selected. For PCGF2, individual replicates from untreated PRC1 CPM ESC were used, and only peaks identified in all biological replicates were taken forward. For all peak sets, peaks overlapping with a custom-build set of blacklisted genomic regions were discarded to remove sequencing artefacts. For RING1B-bound regions, RING1B cChIP-seq in PRC1 CKO ESCs was used to filter out peaks which showed no significant loss of RING1B signal following tamoxifen treatment (p-adj < 0.05 and > 2-fold). In total, we were able to identify 18643 RING1B peaks, 7438 SUZ12 peaks and 3680 PCGF2 peaks. Using the overlap between these peak sets, we defined Polycomb (PcG)-occupied regions as RING1B peaks that overlap SUZ12 peaks (n = 7074), and PCGF2 target sites as RING1B peaks overlapping PCGF2 peaks (n = 3568). To characterise low-level genomic blanket of H2AK119ub1, we have generated a set of 100 kb windows spanning the genome (n = 27,348) using makewindows function from BEDtools (v2.17.0).
Read count quantitation and analysis
For cChIP-seq, computeMatrix and plotProfile/plotHeatmap from deeptools were used to perform metaplot and heatmap analysis of read density at regions of interest. For each cChIP-seq dataset and each cell line, read density at the peak centre in untreated cells was set to 1. For chromosome-wide density plots, read coverage in 250 kb bins was calculated using a custom R script utilising GenomicRanges, GenomicAlignments and Rsamtools Bioconductor packages (Huber et al., 2015) and visualised using ggplot2. For cChIP-seq, target regions of interest were annotated with read counts using multiBamSummary from deeptools ( "--outRawCounts"). For comparative box plot analysis, read counts from merged spike-in normalised replicates were used, while for differential enrichment analysis, read counts from individual biological replicates prior to spike-in normalisation were obtained. For differential gene expression analysis, we used a custom Perl script utilising SAMtools to obtain read counts for a custom-built non-redundant mm10 gene set (n = 20633), derived from mm10 refGene genes by removing very short genes with poor sequence mappability and highly similar transcripts.
Normalised read counts and log2 fold changes for different genomic intervals were visualised using custom R scripts and ggplot2. For box plot analysis of cChIP-seq signal for different factors before and after treatment, read counts were normalised to the genomic region size (in kb) and median value of cChIP-seq signal in untreated cells, log2 of which was set to 1. For box plots comparing H2AK119ub1 enrichment at RING1B-bound sites and 100 kb genomic windows, read density is shown relative to the signal at RING1B-bound sites in untreated cells. For box plots, boxes show interquartile range (IQR) and whiskers extend by 1.5xIQR. To study the relationship between the levels of different factors/histone modifications and gene expression at RING1B-bound genomic regions, the RING1B target sites that overlapped with gene promoters were divided into percentiles based on the expression level of the associated gene in untreated PRC1 CPM cells. For each percentile, mean read density normalised to the genomic region size (in kb) was plotted relative to the mean read density in the fiftieth percentile, together with loess regression trendlines. ggcor function from the GGally (v1.4.0) R package was used to generate a correlation matrix for the association of RING1B occupancy before and after tamoxifen treatment in PRC1 CPM cells with a set of chromatin features and occupancy of other Polycomb factors. All correlation analyses in the paper used Pearson correlation coefficient to measure the strength of the association between the variables and were visualised using scatterplots coloured by density with stat_density2d. Linear regression lines were plotted using stat_poly_eq function from the ggpmisc (v0.3.1) R package, together with the model's R 2 coefficient of determination. Student's t-test and Wilcoxon signed-rank statistical tests were also performed in R with samples considered to be independent and two-sided alternative hypothesis, unless otherwise specified.
For CaptureC, read counts and interaction scores (significance of interactions) for the captured gene promoters were obtained using the Bioconductor package CHiCAGO (Cairns et al., 2016) . For visualisation of CaptureC data, weighted read counts from CHiCAGO data files for merged biological replicates were normalized to the total number of reads aligning to the captured gene promoters and further to the number of promoters in the respective CaptureC experiment. Bigwig files were generated from these normalized read counts. For comparative boxplot analysis, interactions called by CHiCAGO (score >= 5) across all samples were aggregated and interactions with a distance of less than 10 DpnII fragments were merged to a single interaction peak. For each interaction peak, we then quantified mean normalized read count and CHiCAGO scores of all overlapping DpnII fragments.
Differential cChIP-seq enrichment and gene expression analysis
To identify significant changes in cChIP-seq and cRNA-seq, we used a custom R script that incorporates spike-in calibration into DESeq2 analysis (Love et al., 2014) . In order to do this, we used read counts from the spike-in genome at a control set of intervals to calculate DESeq2 size factors for normalisation of raw mm10 read counts (as has been previously described in Taruttis et al., 2017) . Unique dm6 genes from refGene were used for spike-in normalisation of cRNA-seq, while 10 kb (for hg19 spike-in) or 1 kb (for dm6 spike-in) windows spanning the genome were used for differential enrichment analysis of cChIP-seq. Prior to quantification, spike-in reads were prenormalised using the spike-in/mouse read ratio derived from the corresponding Input or genomic DNA-seq sample in order to account for minor variations in mixing of mouse and spike-in cells. For a change to be called significant, we applied a threshold of p-adj < 0.05 and fold change > 1.5, unless otherwise specified. Log2-fold change values were visualised using R and ggplot2 with MA plots and violin plots. For MA plots, density of the data points across y-axis is shown to reflect the general direction of gene expression changes.
